PFIZER - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.8
| Stock Code | PFIZER | Market Cap | 21,502 Cr. | Current Price | 4,705 ₹ | High / Low | 5,993 ₹ |
| Stock P/E | 28.2 | Book Value | 841 ₹ | Dividend Yield | 0.74 % | ROCE | 21.6 % |
| ROE | 16.4 % | Face Value | 10.0 ₹ | DMA 50 | 4,810 ₹ | DMA 200 | 4,927 ₹ |
| Chg in FII Hold | 0.10 % | Chg in DII Hold | -0.16 % | PAT Qtr | 182 Cr. | PAT Prev Qtr | 189 Cr. |
| RSI | 43.8 | MACD | -25.2 | Volume | 14,250 | Avg Vol 1Wk | 12,426 |
| Low price | 4,100 ₹ | High price | 5,993 ₹ | PEG Ratio | 17.9 | Debt to equity | 0.01 |
| 52w Index | 32.0 % | Qtr Profit Var | 43.0 % | EPS | 187 ₹ | Industry PE | 30.9 |
📊 PFIZER shows solid fundamentals for long-term investment. The stock trades at a P/E of 28.2, slightly below the industry average (30.9), suggesting fair valuation. ROE (16.4%) and ROCE (21.6%) are healthy, reflecting efficient capital use. Dividend yield (0.74%) adds modest income appeal. EPS is strong at ₹187, while debt-to-equity (0.01) indicates a virtually debt-free balance sheet. However, PEG ratio (17.9) suggests growth is expensive relative to valuation. Quarterly PAT declined slightly (₹189 Cr. → ₹182 Cr.), showing short-term earnings pressure, though RSI (43.8) indicates the stock is oversold, offering potential accumulation opportunities.
💡 Ideal Entry Price Zone: Accumulation is favorable around ₹4,400–₹4,600, near the recent low (₹4,100) and below DMA 50 (₹4,810). Current price (₹4,705) is close to this zone, making it attractive for gradual accumulation.
📈 Exit Strategy / Holding Period: For existing holders, PFIZER is a strong candidate for long-term holding (5+ years) given its efficiency metrics and stable fundamentals. Exit can be considered near ₹5,800–₹6,000 (recent high zone) if valuations stretch without earnings growth. Otherwise, continue holding for compounding benefits supported by strong balance sheet and dividend yield.
Positive
- 📈 ROCE (21.6%) and ROE (16.4%) show healthy efficiency.
- 📊 EPS at ₹187 reflects strong profitability.
- 💸 Dividend yield (0.74%) provides modest income.
- 📉 Debt-to-equity ratio (0.01) shows virtually debt-free status.
- 📊 FII holdings increased slightly (+0.10%), showing foreign investor confidence.
Limitation
- ⚠️ PEG ratio (17.9) indicates expensive growth.
- 📉 Quarterly PAT declined (₹189 Cr. → ₹182 Cr.).
- 📊 DII holdings decreased (-0.16%), showing weaker domestic support.
Company Negative News
- 📉 Quarterly profit variation is negative (-3.7%).
- 📊 DII holdings declined, reflecting reduced domestic institutional interest.
Company Positive News
- 📈 EPS remains strong despite short-term profit decline.
- 📊 FII holdings increased, reflecting foreign confidence.
- 📉 Debt-free balance sheet ensures financial safety.
Industry
- 💊 Pharma industry PE is 30.9, slightly higher than PFIZER’s 28.2, suggesting fair valuation.
- 📊 Industry growth remains strong, driven by healthcare demand and innovation in drug development.
Conclusion
⚖️ PFIZER is fairly valued with strong ROE, ROCE, and a debt-free balance sheet. Despite short-term profit decline and expensive growth metrics, its long-term prospects remain attractive. Ideal entry is near ₹4,400–₹4,600. Existing holders should continue for 5+ years, with exit considered near ₹5,800–₹6,000 if earnings growth slows. Overall, PFIZER is a solid candidate for long-term portfolios in the pharmaceutical sector.